Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171011 | 1.00 | GPR119 (0.43) | GPR119PIK3CDIKBKETBK1PIK3CA | |
| SCHEMBL756593 | 0.90 | GPR119 (0.44) | GPR119PIK3CD | |
| SCHEMBL756592 | 0.90 | GPR119 (0.44) | GPR119PIK3CD | |
| SCHEMBL756660 | 0.90 | GPR119 (0.35) | GPR119PIK3CD | |
| SCHEMBL759312 | 0.89 | GPR119 (0.37) | GPR119 | |
| SCHEMBL10171013 | 0.89 | GPR119 (0.37) | GPR119 | |
| SCHEMBL13073552 | 0.89 | GPR119 (0.37) | GPR119 | |
| SCHEMBL298072 | 0.81 | GPR119 (0.46) | GPR119PIK3CDIKBKETBK1PIK3CA | |
| SCHEMBL298251 | 0.81 | GPR119 (0.45) | GPR119PIK3CDIKBKETBK1PIK3CA | |
| SCHEMBL1768120 | 0.81 | PIK3CD (0.41) | GPR119PIK3CDIKBKETBK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | GPR119 1/4885PIK3CD 2858/4885IKBKE 3605/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | GPR119 1/4885PIK3CD 2502/4885IKBKE 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.